Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Medicine, discusses data for atezolizumab (Tecentriq) plus platinum/etoposide versus platinum/etoposide alone in patients with small cell lung cancer (SCLC) in the IMpower133 trial.
Brahmer says these data showed that the addition of the immunotherapy improved progression-free survival in these patients. However, it did not improve the response rate.
Atezolizumab clearly maintained the response for longer periods of time compared to the chemotherapy, Brahmer says. This can help in improving overall survival. Moving forward, she says other trials will show whether or not these data remain consistent when combining the PD-1/PD-L1 inhibitors with chemotherapy.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
